Sanofi (NASDAQ:SNY) Hits New 1-Year High – Still a Buy?

Sanofi (NASDAQ:SNY)’s share price hit a new 52-week high on Wednesday . The company traded as high as $59.12 and last traded at $59.12, with a volume of 2131990 shares traded. The stock had previously closed at $57.70.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi presently has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Trading Up 2.4 %

The company has a market capitalization of $149.90 billion, a P/E ratio of 23.72, a PEG ratio of 1.01 and a beta of 0.57. The business has a fifty day moving average of $52.00 and a 200-day moving average of $52.64. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Institutional Trading of Sanofi

Several institutional investors and hedge funds have recently modified their holdings of the stock. Synergy Asset Management LLC bought a new stake in Sanofi during the fourth quarter worth $25,000. McClarren Financial Advisors Inc. boosted its holdings in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the last quarter. Bessemer Group Inc. grew its stake in shares of Sanofi by 59.8% in the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock worth $32,000 after acquiring an additional 242 shares in the last quarter. Lee Danner & Bass Inc. purchased a new stake in shares of Sanofi in the fourth quarter valued at about $31,000. Finally, Sunbelt Securities Inc. lifted its position in shares of Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares in the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.